FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2917253379> ?p ?o ?g. }

• W2917253379 endingPage "952" @default.
• W2917253379 startingPage "943" @default.
• W2917253379 abstract "Background: Surgical resection is the only curative treatment option for gastric cancer. Despite widespread adoption of multimodality perioperative treatment strategies, 5-year overall survival rates remain low. In patients with advanced gastric or gastroesophageal junction adenocarcinoma, pembrolizumab has demonstrated promising efficacy and manageable safety as monotherapy in previously treated patients and as first-line therapy in combination with cisplatin and 5-fluorouracil. Combining chemotherapy with pembrolizumab in the neoadjuvant/adjuvant setting may benefit patients with locally advanced, resectable disease. Aim: To describe the design and rationale for the global, multicenter, randomized, double-blind, Phase III KEYNOTE-585 study to evaluate the efficacy and safety of pembrolizumab plus chemotherapy compared with placebo plus chemotherapy as neoadjuvant/adjuvant treatment for localized gastric or gastroesophageal junction adenocarcinoma. ClinicalTrials.gov : NCT03221426" @default.
• W2917253379 created "2019-03-02" @default.
• W2917253379 creator A5015190461 @default.
• W2917253379 creator A5015799240 @default.
• W2917253379 creator A5018242338 @default.
• W2917253379 creator A5021215219 @default.
• W2917253379 creator A5024904484 @default.
• W2917253379 creator A5035865205 @default.
• W2917253379 creator A5037658285 @default.
• W2917253379 creator A5040552693 @default.
• W2917253379 creator A5049314303 @default.
• W2917253379 creator A5062218155 @default.
• W2917253379 creator A5076298207 @default.
• W2917253379 creator A5078338048 @default.
• W2917253379 creator A5080190853 @default.
• W2917253379 creator A5082058844 @default.
• W2917253379 creator A5090645179 @default.
• W2917253379 date "2019-03-01" @default.
• W2917253379 modified "2023-10-10" @default.
• W2917253379 title "KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer" @default.
• W2917253379 cites W1757407923 @default.
• W2917253379 cites W1893566975 @default.
• W2917253379 cites W1977468182 @default.
• W2917253379 cites W1999075493 @default.
• W2917253379 cites W2066671159 @default.
• W2917253379 cites W2077968480 @default.
• W2917253379 cites W2113947048 @default.
• W2917253379 cites W2115072149 @default.
• W2917253379 cites W2137991416 @default.
• W2917253379 cites W2145135839 @default.
• W2917253379 cites W2146834306 @default.
• W2917253379 cites W2300582328 @default.
• W2917253379 cites W2347070489 @default.
• W2917253379 cites W2521503673 @default.
• W2917253379 cites W2586797882 @default.
• W2917253379 cites W2622319425 @default.
• W2917253379 cites W2623425472 @default.
• W2917253379 cites W2742446628 @default.
• W2917253379 cites W2762052313 @default.
• W2917253379 cites W2763064222 @default.
• W2917253379 cites W2764292634 @default.
• W2917253379 cites W2774830604 @default.
• W2917253379 cites W2793364080 @default.
• W2917253379 cites W2806614796 @default.
• W2917253379 cites W2917837889 @default.
• W2917253379 cites W4211007657 @default.
• W2917253379 cites W4211130279 @default.
• W2917253379 cites W4242151806 @default.
• W2917253379 cites W995625926 @default.
• W2917253379 doi "https://doi.org/10.2217/fon-2018-0581" @default.
• W2917253379 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30777447" @default.
• W2917253379 hasPublicationYear "2019" @default.
• W2917253379 type Work @default.
• W2917253379 sameAs 2917253379 @default.
• W2917253379 citedByCount "115" @default.
• W2917253379 countsByYear W29172533792019 @default.
• W2917253379 countsByYear W29172533792020 @default.
• W2917253379 countsByYear W29172533792021 @default.
• W2917253379 countsByYear W29172533792022 @default.
• W2917253379 countsByYear W29172533792023 @default.
• W2917253379 crossrefType "journal-article" @default.
• W2917253379 hasAuthorship W2917253379A5015190461 @default.
• W2917253379 hasAuthorship W2917253379A5015799240 @default.
• W2917253379 hasAuthorship W2917253379A5018242338 @default.
• W2917253379 hasAuthorship W2917253379A5021215219 @default.
• W2917253379 hasAuthorship W2917253379A5024904484 @default.
• W2917253379 hasAuthorship W2917253379A5035865205 @default.
• W2917253379 hasAuthorship W2917253379A5037658285 @default.
• W2917253379 hasAuthorship W2917253379A5040552693 @default.
• W2917253379 hasAuthorship W2917253379A5049314303 @default.
• W2917253379 hasAuthorship W2917253379A5062218155 @default.
• W2917253379 hasAuthorship W2917253379A5076298207 @default.
• W2917253379 hasAuthorship W2917253379A5078338048 @default.
• W2917253379 hasAuthorship W2917253379A5080190853 @default.
• W2917253379 hasAuthorship W2917253379A5082058844 @default.
• W2917253379 hasAuthorship W2917253379A5090645179 @default.
• W2917253379 hasBestOaLocation W29172533791 @default.
• W2917253379 hasConcept C121608353 @default.
• W2917253379 hasConcept C126322002 @default.
• W2917253379 hasConcept C141071460 @default.
• W2917253379 hasConcept C143998085 @default.
• W2917253379 hasConcept C2776694085 @default.
• W2917253379 hasConcept C2777701055 @default.
• W2917253379 hasConcept C2777863537 @default.
• W2917253379 hasConcept C2778292576 @default.
• W2917253379 hasConcept C2780057760 @default.
• W2917253379 hasConcept C2781182431 @default.
• W2917253379 hasConcept C31174226 @default.
• W2917253379 hasConcept C530470458 @default.
• W2917253379 hasConcept C71924100 @default.
• W2917253379 hasConceptScore W2917253379C121608353 @default.
• W2917253379 hasConceptScore W2917253379C126322002 @default.
• W2917253379 hasConceptScore W2917253379C141071460 @default.
• W2917253379 hasConceptScore W2917253379C143998085 @default.
• W2917253379 hasConceptScore W2917253379C2776694085 @default.
• W2917253379 hasConceptScore W2917253379C2777701055 @default.
• W2917253379 hasConceptScore W2917253379C2777863537 @default.
• W2917253379 hasConceptScore W2917253379C2778292576 @default.

• next